Clin Exp Vaccine Res.  2016 Jul;5(2):175-178. 10.7774/cevr.2016.5.2.175.

A Bordetella pertussis proteoliposome induces protection in mice without affecting the immunogenicity of diphtheria and tetanus toxoids in a trivalent formulation

• Castillo S
• Chovel ML
• Hernández NG
• González
• Blanco A
• Hernández DS
• Medina MF
• Tito MA
• Quiñoy JL

• KMID: 2421565
• DOI: http://doi.org/10.7774/cevr.2016.5.2.175

Abstract

In this study, a formulation of Bordetella pertussis proteoliposome (PLBp), diphtheria, and tetanus toxoids and alum (DT-PLBp) was evaluated as a trivalent vaccine candidate in BALB/c mice. Vaccine-induced protection was estimated using the intranasal challenge for pertussis and enzyme-linked immunosorbent assay fvto assess serological responses for diphtheria or tetanus. Both, diphtheria-tetanus-whole cell pertussis (DTP) and diphtheria-tetanus vaccines (DT) were used as controls. Animals immunized with DT-PLBp, PLBp alone, and DTP showed total reduction of CFU in lungs 7 days after intranasal challenge. Likewise, formulations DT-PLBp, DTP, and DT elicited antibody levels ≥2 IU/mL against tetanus and diphtheria, considered protective when neutralization tests are used. Overall, results showed that combination of PLBp with tetanus and diphtheria toxoids did not affect the immunogenicity of each antigen alone.

Keyword

Bordetella pertussis; Proteoliposome; Whooping cough; Vaccines

MeSH Terms

Animals
Bordetella pertussis*
Bordetella*
Diphtheria Toxoid
Diphtheria*
Enzyme-Linked Immunosorbent Assay
Lung
Mice*
Neutralization Tests
Tetanus Toxoid*
Tetanus*
Vaccines
Whooping Cough
Diphtheria Toxoid
Tetanus Toxoid
Vaccines

Figure

• 

  Fig. 1 Immune response anti-tetanus toxoid by enzyme-linked immunosorbent assay. Groups were immunized with two doses (3 weeks apart) and 2 weeks after the second dose, blood samples were taken from 10 mice per group. DTP, diphtheria-tetanus-whole cell pertussis vaccine; DT, diphtheria-tetanus vaccine; PLBp, B. pertussis proteoliposome; DT-PLBp, diphtheria-tetanus and B. pertussis proteoliposome. Comparison of arithmetic means was carried out by simple ANOVA and confidence levels (p<0.05) by Tukey's multiple comparison test.

• 

  Fig. 2 Immune response anti-diphtheria toxoid by enzyme-linked immunosorbent assay. Groups were immunized with two doses (3 weeks apart) and 2 weeks after the second dose blood samples were taken from 10 mice per group. DTP, diphtheria-tetanus-whole cell pertussis vaccine; DT, diphtheria-tetanus vaccine; PLBp, B. pertussis proteoliposome; DT-PLBp, diphtheria-tetanus and B. pertussis proteoliposome. Comparison of arithmetic means was carried out by simple ANOVA and confidence levels (p<0.05) by Tukey's multiple comparison test.

Reference

1. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec. 2010; 85:385–400.

2. Cherry JD. Why do pertussis vaccines fail? Pediatrics. 2012; 129:968–970.

3. Storsaeter J, Wolter J. Is there a need for a new generation of vaccines against pertussis? Expert Opin Emerg Drugs. 2006; 11:195–205.

4. Meade BD, Plotkin SA, Locht C. Possible options for new pertussis vaccines. J Infect Dis. 2014; 209:Suppl 1. S24–S27.

5. Acevedo R, Fernandez S, Zayas C, et al. Bacterial outer membrane vesicles and vaccine applications. Front Immunol. 2014; 5:121.

6. Sierra GV, Campa HC, Varcacel NM, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991; 14:195–207.

7. Fernandez S, Fajardo EM, Mandiarote A, et al. A proteoliposome formulation derived from Bordetella pertussis induces protection in two murine challenge models. BMC Immunol. 2013; 14:Suppl 1. S8.

8. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev. 2005; 18:326–382.

9. Chovel ML, Mandiarote A, Ontivero I, et al. Development of 3Rs alternatives for determining potency and toxicity of vaccines in Cuba: current challenges and research projects in progress. ALTEX. 2012; 29:71–76.

10. Guiso N, Capiau C, Carletti G, Poolman J, Hauser P. Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines. Vaccine. 1999; 17:2366–2376.

11. WHO/UNICEF coverage estimates 2012 revision, July 2013. 194 WHO Member States. Map production: immunization vaccines and biologicals (IVB). Geneva: World Health Organization;2013.

12. Forsyth KD, Wirsing von Konig CH, Tan T, Caro J, Plotkin S. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine. 2007; 25:2634–2642.

13. Mooi FR, Van Der Maas NA, De Melker HE. Pertussis resurgence: waning immunity and pathogen adaptation: two sides of the same coin. Epidemiol Infect. 2014; 142:685–694.